Navitoclax has been studied in 292 papers since 2010: 2 trials and 16 observational studies in people, 185 in animals, 56 in cells, 31 reviews; 67 in the past year. Its furthest trials in people are at phase 3. The newest story, Nov 16, 2026: “Protein levels alter drug sensitivity in lab-grown human cells”.
Navitoclax reduces cellular senescence in mice across independent labs, although a finding shows no clear effect and inflammation changes in both directions. It increases mortality in mice with advanced atherosclerosis and causes thrombocytopenia in human trials, also reproduced by independent labs. Its registered trials are not classified as aging trials; most are developer-sponsored.
281 findings in 123 papers from 2010 to 2026, 13 of them since April 2026
Independent labs found the same change in cells, mice and people. 82 independent labs in 20 countries; 28 trials, none about aging, 10 with no results posted.
“Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”
Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
82 independent labs in 20 countries
4 findings against
28 trials, none about aging, 10 with no results posted
Funders: National Institutes of Health and others
41 of 275 findings with company ties
17 of 28 trials sponsored by its developers
Human trial2
Humans16
Animals184
Model organisms1
Cells56
In silico1
Studies in people
1 study gave navitoclax to people and measured what changed.
Studies of navitoclax measured 198 outcomes; the most studied are cellular senescence (20 studies), inflammation (9) and senescence-associated secretory phenotype (SASP) (7).
Cellular senescence
↓downin mice13↓downin human cells2↓downin mouse cells2↓downin rats2+1−80%
20 studies
Navitoclax decreases cellular senescence in human cells.
“Pharmacologic reduction of senescent cells with Navitoclax shifts aged RPE toward a younger transcriptional profile”
Navitoclax decreases cellular senescence in APP/PS1 mice.
“ABT263 protected neurons against Aβ pathology, reduced the accumulation of senescent cells, and improved cognitive decline by enhancing PI3K/AKT/GSK-3 activity.”
Animalsin APP/PS1 micehippocampustwo cycles of five days eachn = 16
Navitoclax decreases cellular senescence in 1,25(OH)2D-insufficient mice.
“ABT263 corrected bone cell senescence and SASP caused by 1,25(OH)2D insufficiency by reducing the expression of senescence and SASP-related genes and proteins.”
Navitoclax decreases cellular senescence in spontaneously and TNF-induced senescent CAFs.
“senolytic drugs, navitoclax and the combination of dasatinib/quercetin, reduced the number of spontaneously senescent and TNF-induced senescent CAFs.”
Cellsin spontaneously and TNF-induced senescent CAFs
Navitoclax inhibits cellular senescence in chronic graft-versus-host disease mice.
“The expression of these cellular senescence-associated molecules was considerably suppressed in ABT-263-treated eyelids compared to that in vehicle-treated ones.”
Navitoclax decreases inflammation in chronic graft-versus-host disease mice.
“Pathological and immunohistochemical examinations revealed significant reductions in eyelid tissue inflammation and pathological fibrosis in the ABT-263 group compared to that in the vehicle-treated group.”
Navitoclax decreases senescence-associated secretory phenotype (SASP) in APP/PS1 mice.
“ABT263 treatment led to a decline in senescence-associated β-galactosidase activity, p16 senescence-related gene expression, and the expression of SASP-associated proteins, including IL-6, IL-8, and MMP-1.”
Animalsin APP/PS1 micehippocampustwo cycles of five days eachn = 16
Navitoclax decreases senescence-associated secretory phenotype (SASP) in 1,25(OH)2D-insufficient mice.
“ABT263 corrected bone cell senescence and SASP caused by 1,25(OH)2D insufficiency by reducing the expression of senescence and SASP-related genes and proteins.”
“Senescent human skin treated with ABT-263 exhibited a decrease in the number of senescent cells and in the expression of aging-related secretory phenotype molecules”
Journal of the European Academy of Dermatology and Venereology : JEADV·
Navitoclax decreases senescence-associated secretory phenotype (SASP) in cells (through elimination of senescent cells).
“selective elimination of senescent cells alleviates SASP and micronuclei-mediated the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) activation”
Navitoclax induces apoptosis in cells (added after irradiation, compared with radiation alone).
“the addition of senolytic agents Venetoclax (ABT-199) or Navitoclax (ABT-263) after irradiation induced a rapid apoptotic cell death in STS monolayer cultures”
Cellsadded after irradiation, compared with radiation alone
“ABT-263 is unlikely to be approved for the clinical treatment of solid tumors due to both on-target (thrombocytopenia) and off-target (neutropenia) toxicities”
Navitoclax decreases scar size after cardiac ischemia-reperfusion injury.
“treatment with the senolytic drug navitoclax after ischemia-reperfusion improves left ventricular function, increases myocardial vascularization, and decreases scar size”
Navitoclax induces T cell lymphopenia in humans (attributed to high-affinity BCL-2 inhibition) (grade 3 or 4 lymphocytopenia in 18 patients).
“Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”
Human trialattributed to high-affinity BCL-2 inhibition
Navitoclax induces peripheral thrombocytopenia in humans (attributed to high-affinity BCL-XL inhibition) (grade 3 or 4 thrombocytopenia in 29 patients).
“Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”
Human trialattributed to high-affinity BCL-XL inhibition
“There was a significant reduction following a single dose of navitoclax, which was observed to begin as soon as one hour after dosing (data not shown).”
Navitoclax lowers the risk of cerebral microhemorrhage in mice (hypertension induced by angiotensin-II and L-NAME).
“Notably, the senolytic pre-treatment wielded considerable cerebromicrovascular protection, effectively delaying the onset, mitigating the incidence, and diminishing the severity of CMHs.”
Animalshypertension induced by angiotensin-II and L-NAMEbrain
Navitoclax raises the risk of thrombocytopenia in humans (29 patients).
“Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”
Navitoclax decreases cellular senescence in mice across independent labs; independent labs also report increased inflammation in mice and decreased inflammation in rats. One group reports thrombocytopenia in a human trial whose paper declares developer ties; most trials are developer-sponsored. None of its registered trials concern aging, and 10 ended over a year ago without posted results.
Navitoclax extends lifespan with cyclic dosing in Titan mice; independent labs reproduce reduced senescence and SASP in mice. In mice with advanced atherosclerosis, it increases mortality without shrinking lesions. None of its registered trials is judged aging-related; ten ended over a year ago without posted results or citing papers, and most trials are sponsored by AbbVie and Genentech.
Summary rewritten as its findings changed.
As it read before
Navitoclax reduces cardiac senescence, hypertrophy and scarring and increases angiogenesis after ischemia–reperfusion injury in male mice in a preprint. A cell study reports reduced senescent cells and M. abscessus burden; a zebrafish study reports fewer senescent hepatocytes with high UHRF1.
Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.
An experiment tested navitoclax in mice with diet-induced liver disease; the packaged drug also reduced a disease activity score and scarring-related profiles.An experiment tested navitoclax in mice with diet-induced liver disease; the packaged drug also reduced a disease activity score and scarring-related profiles.
In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.
In an experiment with at least 10 mice per group, ABT-263 also depleted connective-tissue and immune cells linked to scarring.In an experiment with at least 10 mice per group, ABT-263 also depleted connective-tissue and immune cells linked to scarring.
In laboratory experiments, reducing the protein weakened two drugs’ cell-killing effects without changing the usual signs of senescence, a state in which cells stop…In laboratory experiments, reducing the protein weakened two drugs’ cell-killing effects without changing the usual signs of senescence, a state in which cells stop dividing.
Researchers found that senescent epithelial cells secrete TGF-beta1 to reprogram fibroblasts into a matrix-remodeling state, which senolytic treatment can blunt.Researchers found that senescent epithelial cells secrete TGF-beta1 to reprogram fibroblasts into a matrix-remodeling state, which senolytic treatment can blunt.
High UHRF1 expression causes stable senescence sensitive to Navitoclax, while cells with lower expression proliferate if tp53 is mutated.High UHRF1 expression causes stable senescence sensitive to Navitoclax, while cells with lower expression proliferate if tp53 is mutated.